Experimental models of human bladder carcinogenesis

Carcinogenesis

Volumn 27, Issue 3, 2006, Pages 374-381

  Crallan, R A ^a   Georgopoulos, N T ^a   Southgate, J ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYLANILINE; 4 BIPHENYLAMINE; ANTINEOPLASTIC AGENT; AROMATIC AMINE; CISPLATIN; CYCLIN DEPENDENT KINASE 4; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 3; INDUSTRIAL CHEMICAL; METHOTREXATE; MITOMYCIN C; MULTIDRUG RESISTANCE PROTEIN 1; MYC PROTEIN; NITROSO DERIVATIVE; PHENACETIN; PROTEIN BCL 2; PROTEIN E6; PROTEIN P16; PROTEIN P16INK4A; PROTEIN P21; PROTEIN P53; RETINOBLASTOMA PROTEIN; SACCHARIN SODIUM; SMALL INTERFERING RNA; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; BLADDER CARCINOGENESIS; BLADDER CARCINOMA; BLADDER EPITHELIUM; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER RESISTANCE; CANCER RISK; CARCINOGENICITY; CYSTECTOMY; DISEASE COURSE; DRUG EFFICACY; DRUG EXPOSURE; DRUG RESPONSE; DRUG SENSITIVITY; GAMMA RADIATION; GENE TARGETING; GENETIC MANIPULATION; GENETIC POLYMORPHISM; GENOTOXICITY; HUMAN; MALIGNANT TRANSFORMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SMOKING;

ANIMALS; CARCINOGENS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; MODELS, THEORETICAL; RODENTIA; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 33644898559     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgi266     Document Type: Review

References (137)

1. Kroft,S.H. and Oyasu,R. (1994) Urinary bladder cancer: Mechanisms of development and progression. Lab. Invest., 71, 158-174.
2. Harnden,P., Mahmood,N. and Southgate,J. (1999) Expression of cytokeratin 20 redefines urothelial papillomas of the bladder. Lancet, 353, 974-977.
3. Cote,R.J. and Datar,R.H. (2003) Therapeutic approaches to bladder cancer: Identifying targets and mechanisms. Crit. Rev. Oncol. Hematol., 46 (Suppl.), S67-S83.
4. Spruck,C.H.,III, Ohneseit,P.F., Gonzalez-Zulueta,M., Esrig,D., Miyao,N., Tsai,Y.C., Lerner,S.P., Schmutte,C., Yang,A.S., Cote,R. et al. (1994) Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res., 54, 784-788.
5. Pollack,A., Czerniak,B., Zagars,G.K., Hu,S.X., Wu,C.S., Dinney,C.P., Chyle,V. and Benedict,W.F. (1997) Retinoblastoma protein expression and radiation response in muscle-invasive bladder cancer. Int. J. Radiat. Oncol. Biol. Phys., 39, 687-695.
6. Bakkar,A.A., Wallerand,H., Radvanyi,F. et al. (2003) FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res., 63, 8108-8112.
7. van Rhijn,B.W., van der Kwast,T.H., Vis,A.N., Kirkels,W.J., Boeve,E.R., Jobsis,A.C. and Zwarthoff,E.C. (2004) FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res., 64, 1911-1914.
8. Marceau,N. (1990) Cell lineages and differentiation programs in epidermal, urothelial and hepatic tissues and their neoplasms. Lab. Invest., 63, 4-20.
9. Limas,C., Bair,R., Bernhart,P. and Reddy,P. (1993) Proliferative activity of normal and neoplastic urothelium and its relation to epidermal growth factor and transferrin receptors. J. Clin. Pathol., 46, 810-816.
10. Stewart,F.A. (1986) Mechanism of bladder damage and repair after treatment with radiation and cytostatic drugs. Br. J. Cancer Suppl., 7, 280-291.
11. Zeegers,M.P., Tan,F.E., Dorant,E. and van Den Brandt,P.A. (2000) The impact of characteristics of cigarette smoking on urinary tract cancer risk: A meta-analysis of epidemiologic studies. Cancer, 89, 630-639.
12. Cartwright,R.A., Adib,R., Glashan,R. and Gray,B.K. (1981) The epidemiology of bladder cancer in West Yorkshire. A preliminary report on non-occupational aetiologies. Carcinogenesis, 2, 343-347.
13. Augustine,A., Hebert,J.R., Kabat,G.C. and Wynder,E.L. (1988) Bladder cancer in relation to cigarette smoking. Cancer Res., 48, 4405-4408.
14. Wynder,E.L., Augustine,A., Kabat,G.C. and Hebert,J.R. (1988) Effect of the type of cigarette smoked on bladder cancer risk [Erratum (1988) Cancer, 61, 1319.]. Cancer, 61, 622-627.
15. Pitard,A., Brennan,P., Clavel,J., Greiser,E., Lopez-Abente,G., Chang-Claude,J., Wahrendorf,J., Serra,C., Kogevinas,M. and Boffetta,P. (2001) Cigar, pipe, and cigarette smoking and bladder cancer risk in European men. Cancer Causes Control, 12, 551-556.
16. Bartsch,H., Caporaso,N., Coda,M., Kadlubar,F., Malaveille,C., Skipper,P., Talaska,G., Tannenbaum,S.R. and Vineis,P. (1990) Carcinogen hemoglobin adducts, urinary mutagenicity, and metabolic phenotype in active and passive cigarette smokers. J. Natl Cancer Inst., 82, 1826-1831.
17. Granella,M., Priante,E., Nardini,B., Bono,R. and Clonfero,E. (1996) Excretion of mutagens, nicotine and its metabolites in urine of cigarette smokers. Mutagenesis, 11, 207-211.
18. Grimmer,G., Dettbarn,G., Seidel,A. and Jacob,J. (2000) Detection of carcinogenic aromatic amines in the urine of non-smokers. Sci. Total Environ., 247, 81-90.
19. Talaska,G., al-Juburi,A.Z. and Kadlubar,F.F. (1991) Smoking related carcinogen-DNA adducts in biopsy samples of human urinary bladder: identification of N-(deoxyguanosin-8-yl)-4-aminobiphenyl as a major adduct. Proc. Natl Acad. Sci. USA, 88, 5350-5354.
20. Talaska,G., Schamer,M., Skipper,P., Tannenbaum,S., Caporaso,N., Unruh,L., Kadlubar,F.F., Bartsch,H., Malaveille,C. and Vineis,P. (1991) Detection of carcinogen-DNA adducts in exfoliated urothelial cells of cigarette smokers: Association with smoking, hemoglobin adducts, and urinary mutagenicity. Cancer Epidemiol. Biomarkers Prev., 1, 61-66.
21. Vineis,P., Talaska,G., Malaveille,C., Bartsch,H., Martone,T., Sithisarankul,P. and Strickland,P. (1996) DNA adducts in urothelial cells: Relationship with biomarkers of exposure to arylamines and polycyclic aromatic hydrocarbons from tobacco smoke. Int. J. Cancer, 65, 314-316.
22. Curigliano,G., Zhang,Y.J., Wang,L.Y., Flamini,G., Alcini,A., Ratto,C., Giustacchini,M., Alcini,E., Cittadini,A. and Santella,R.M. (1996) Immunohistochemical quantitation of 4-aminobiphenyl-DNA adducts and p53 nuclear overexpression in T1 bladder cancer of smokers and nonsmokers. Carcinogenesis, 17, 911-916.
23. Martone,T., Airoldi,L., Magagnotti,C., Coda,R., Randone,D., Malaveille,C., Avanzi,G., Merletti,F., Hautefeuille,A. and Vineis,P. (1998) 4-Aminobiphenyl-DNA adducts and p53 mutations in bladder cancer. Int. J. Cancer, 75, 512-516.
24. Wiencke,J.K. (2002) DNA adduct burden and tobacco carcinogenesis. Oncogene, 21, 7376-7391.
25. Bryant,M.S., Vineis,P., Skipper,P.L. and Tannenbaum,S.R. (1988) Hemoglobin adducts of aromatic amines: Associations with smoking status and type of tobacco. Proc. Natl Acad. Sci. USA, 85, 9788-9791.
26. Peluso,M., Airoldi,L., Armelle,M., Martone,T., Coda,R., Malaveille,C., Giacomelli,G., Terrone,C., Casetta,G. and Vineis,P. (1998) White blood cell DNA adducts, smoking, and NAT2 and GSTM1 genotypes in bladder cancer: A case-control study. Cancer Epidemiol. Biomarkers. Prev., 7, 341-346.
27. Vineis,P. (1992) The use of biomarkers in epidemiology: The example of bladder cancer. Toxicol. Lett., 64-65, 463-467.
28. Feng,Z., Hu,W., Rom,W.N., Beland,F.A. and Tang,M.S. (2002) 4-Aminobiphenyl is a major etiological agent of human bladder cancer: evidence from its DNA binding spectrum in human p53 gene. Carcinogenesis, 23, 1721-1727.
29. Wallerand,H., Bakkar,A.A., de Medina,S.G. et al. (2005) Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: Contribution of exogenous versus endogenous carcinogens. Carcinogenesis, 26, 177-184.
30. Cohen,S.M. (1998) Cell proliferation and carcinogenesis. Drug Metab. Rev., 30, 339-357.
31. Mungan,N.A., Aben,K.K., Schoenberg,M.P., Visser,O., Coebergh,J.W., Witjes,J.A. and Kiemeney,L.A. (2000) Gender differences in stage-adjusted bladder cancer survival. Urology, 55, 876-880.
32. Silverman,D.T., Hartge,P., Morrison,A.S. and Devesa,S.S. (1992) Epidemiology of bladder cancer. Hematol. Oncol. Clin. North Am., 6, 1-30.
33. Ortiz,A., Gonzalez-Parra,E., Alvarez-Costa,G. and Egido,J. (1992) Bladder cancer after cyclophosphamide therapy for lupus nephritis. Nephron, 60, 378-379.
34. Petersen,I., Ohgaki,H., Ludeke,B.I. and Kleihues,P. (1993) p53 mutations in phenacetin-associated human urothelial carcinomas. Carcinogenesis, 14, 2119-2122.
35. Hicks,R.M., Walters,C.L., Elsebai,I., Aasser,A.B., Merzabani,M.E. and Gough,T.A. (1977) Demonstration of nitrosamines in human urine: preliminary observations on a possible etiology for bladder cancer in association with chronic urinary tract infections. Proc. R. Soc. Med., 70, 413-417.
36. La Vecchia,C., Negri,E., D'Avanzo,B., Savoldelli,R. and Franceschi,S. (1991) Genital and urinary tract diseases and bladder cancer. Cancer Res., 51, 629-631.
37. Kawai,K., Yamamoto,M., Kameyama,S., Kawamata,H., Rademaker,A. and Oyasu,R. (1993) Enhancement of rat urinary bladder tumorigenesis by lipopolysaccharide-induced inflammation. Cancer Res., 53, 5172-5175.
38. Gelfand,M., Weinberg,R.W. and Castle,W.M. (1967) Relation between carcinoma of the bladder and infestation with Schistosoma haematobium. Lancet., 1, 1249-1251.
39. Mostafa,M.H., Sheweita,S.A. and O'Connor,P.J. (1999) Relationship between schistosomiasis and bladder cancer. Clin. Microbiol. Rev., 12, 97-111.
40. El-Aaser,A.A., El-Merzabani,M.M., Abdel-Reheem,K.A. and Hamza,B.M. (1982) A study on the etiological factors of bilharzial bladder cancer in Egypt: 4. beta-carotene and vitamin A level in serum. Tumori, 68, 19-22.
41. Wu,R.L., Osman,I., Wu,X.R., Lu,M.L., Zhang,Z.F., Liang,F.X., Hamza,R., Scher,H., Cordon-Cardo,C. and Sun,T.T. (1998) Uroplakin II gene is expressed in transitional cell carcinoma but not in bilharzial bladder squamous cell carcinoma: Alternative pathways of bladder epithelial differentiation and tumor formation [Erratum (1998) Cancer Res., 58, 2904]. Cancer Res., 58, 1291-1297.
42. Miller,M.C.,III, Mohrenweiser,H.W. and Bell,D.A. (2001) Genetic variability in susceptibility and response to toxicants. Toxicol. Lett., 120, 269-280.
43. Baselli,E.C. and Greenberg,R.E. (2000) Intravesical therapy for superficial bladder cancer. Oncology (Williston Park), 14, 719-729.
44. Jauhiainen,K. and Alfthan,O. (1987) Instillation of mitomycin C and doxorubicin in the prevention of recurrent superficial (Ta-T1) bladder cancer. Br. J. Urol., 60, 54-59.
45. Clifford,S.C., Thomas,D.J., Neal,D.E. and Lunec,J. (1994) Increased mdr1 gene transcript levels in high-grade carcinoma of the bladder determined by quantitative PCR-based assay. Br. J. Cancer, 69, 680-686.
46. Clifford,S.C., Neal,D.E. and Lunec,J. (1996) Alterations in expression of the multidrug resistance-associated protein (MRP) gene in high-grade transitional cell carcinoma of the bladder. Br. J. Cancer, 73, 659-666.
47. Waldman,T., Kinzler,K.W. and Vogelstein,B. (1995) p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res., 55, 5187-5190.
48. Cote,R.J., Esrig,D., Groshen,S., Jones,P.A. and Skinner,D.G. (1997) p53 and treatment of bladder cancer. Nature, 385, 123-125.
49. Flamm,M., Brodowicz,T., Haitel,A., Susani,M., Tomek,S., Kostler,W., Pycha,A., Kratzik,C., Marberger,M. and Zielinski,C.C. (2002) Correlation of clinical outcome with p53 and p21 status in patients with advanced transitional-cell carcinoma treated with paclitaxel and carboplatin. Anticancer Res., 22, 1295-1300.
50. Pollack,A. and Zagars,G.Z. (1996) Radiotherapy for stage T3b transitional cell carcinoma of the bladder. Semin. Urol. Oncol., 14, 86-95.
51. Moonen,L., Ong,F., Gallee,M., Verheij,M., Horenblas,S., Hart,A.A. and Bartelink,H. (2001) Apoptosis, proliferation and p53, cyclin D1, and retinoblastoma gene expression in relation to radiation response in transitional cell carcinoma of the bladder. Int. J. Radiat. Oncol. Biol. Phys., 49, 1305-1310.
52. Rodel,C., Grabenbauer,G.G., Rodel,F. et al. (2000) Apoptosis, p53, bcl-2, and Ki-67 in invasive bladder carcinoma: Possible predictors for response to radiochemotherapy and successful bladder preservation. Int. J. Radiat. Oncol. Biol. Phys., 46, 1213-1221.
53. Hicks,R.M. (1980) Multistage carcinogenesis in the urinary bladder. Br. Med. Bull., 36, 39-46.
54. Owens,D.M., Wei,S. and Smart,R.C. (1999) A multihit, multistage model of chemical carcinogenesis. Carcinogenesis, 20, 1837-1844.
55. Zhang,Z.T., Pak,J., Shapiro,E., Sun,T.T. and Wu,X.R. (1999) Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma. Cancer Res., 59, 3512-3517.
56. Hicks,R.M. and Wakefield,J.S. (1972) Rapid induction of bladder cancer in rats with N-methyl-N-nitrosourea. I. Histology. Chem. Biol. Interact., 5, 139-152.
57. Wakefield,J.S. and Hicks,R.M. (1973) Bladder cancer and N-methyl-N-nitrosourea. II. Sub-cellular changes associated with a single non-carcinogenic dose of MNU. Chem. Biol. Interact., 7, 165-179.
58. Hicks,R.M., Wakefield,J. and Chowaniec,J. (1975) Evaluation of a new model to detect bladder carcinogens or co-carcinogens; results obtained with saccharin, cyclamate and cyclophosphamide. Chem. Biol. Interact., 11, 225-233.
59. Ito,N. (1986) Organ-specific modifying effects of phenobarbital, saccharin and antioxidants on 2-stage chemical carcinogenesis. Dev. Toxicol. Environ. Sci., 12, 359-369.
60. Masui,T., Mann,A.M., Garland,E.M. and Cohen,S.M. (1989) Strong promoting activity by uracil on urinary bladder carcinogenesis and a possible inhibitory effect on thyroid tumorigenesis in rats initiated with N-methyl-N-nitrosourea. Carcinogenesis, 10, 1471-1474.
61. Uwagawa,S., Tsuda,H., Inoue,T., Tagawa,Y., Aoki,T., Kagawa,M., Ogiso,T. and Ito,N. (1991) Enhancing potential of 6 different carcinogens on multi-organ tumorigenesis after initial treatment with N-methyl-N-nitrosourea in rats. Jpn. J. Cancer Res., 82, 1397-1405.
62. Poirier,M.C., Fullerton,N.F., Smith,B.A. and Beland,F.A. (1995) DNA adduct formation and tumorigenesis in mice during the chronic administration of 4-aminobiphenyl at multiple dose levels. Carcinogenesis, 16, 2917-2921.
63. West,R.W., Sheldon,W.G., Gaylor,D.W., Haskin,M.G., Delongchamp,R.R. and Kadlubar,F.F. (1986) The effects of saccharin on the development of neoplastic lesions initiated with N-methyl-N-nitrosourea in the rat urothelium. Fundam. Appl. Toxicol., 7, 585-600.
64. Masui,T., Mann,A.M., Macatee,T.L., Okamura,T., Garland,E.M., Fujii,H., Pelling,J.C. and Cohen,S.M. (1991) H-ras mutations in rat urinary bladder carcinomas induced by N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide and sodium saccharin, sodium ascorbate, or related salts. Cancer Res., 51, 3471-3475.
65. Cohen,S.M. and Lawson,T.A. (1995) Rodent bladder tumors do not always predict for humans. Cancer Lett., 93, 9-16.
66. Hahn,W.C. and Weinberg,R.A. (2002) Modelling the molecular circuitry of cancer. Nat. Rev. Cancer, 2, 331-341.
67. Wang,C.Y., Yamada,H., Morton,K.C., Zukowski,K., Lee,M.S. and King,C.M. (1988) Induction of repair synthesis of DNA in mammary and urinary bladder epithelial cells by N-hydroxy derivatives of carcinogenic arylamines. Cancer Res., 48, 4227-4232.
68. 32P-postlabelling and subsequent thin-layer and high-pressure liquid chromatography. Carcinogenesis, 11, 639-646.
69. Kadlubar,F.F., Dooley,K.L., Teitel,C.H., Roberts,D.W., Benson,R.W., Butler,M.A., Bailey,J.R., Young,J.F., Skipper,P.W. and Tannenbaum,S.R. (1991) Frequency of urination and its effects on metabolism, pharmacokinetics, blood hemoglobin adduct formation, and liver and urinary bladder DNA adduct levels in beagle dogs given the carcinogen 4-aminobiphenyl. Cancer Res., 51, 4371-4377.
70. Zhang,Z.T., Pak,J., Huang,H.Y., Shapiro,E., Sun,T.T., Pellicer,A. and Wu,X.R. (2001) Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation. Oncogene, 20, 1973-1980.
71. Cheng,J., Huang,H., Zhang,Z.T., Shapiro,E., Pellicer,A., Sun,T.T. and Wu,X.R. (2002) Overexpression of epidermal growth factor receptor in urothelium elicits urothelial hyperplasia and promotes bladder tumor growth. Cancer Res., 62, 4157-4163.
72. Cheng,J., Huang,H., Pak,J., Shapiro,E., Sun,T.T., Cordon-Cardo,C., Waldman,F.M. and Wu,X.R. (2003) Allelic loss of p53 gene is associated with genesis and maintenance, but not invasion, of mouse carcinoma in situ of the bladder. Cancer Res., 63, 179-185.
73. Garcia-Espana,A., Salazar,E., Sun,T.T. Wu,X.R. and Pellicer,A. (2005) Differential expression of cell cycle regulators in phenotypic variants of transgenically induced bladder tumors: Implications for tumor behavior. Cancer Res., 65, 1150-1157.
74. Johnson,M.D., Bryan,G.T. and Reznikoff,C.A. (1985) Serial cultivation of normal rat bladder epithelial cells in vitro. J. Urol., 133, 1076-1081.
75. Knowles,M.A. and Jani,H. (1986) Multistage transformation of cultured rat urothelium: The effects of N-methyl-N-nitrosourea, sodium saccharin, sodium cyclamate and 12-O-tetradecanoylphorbol-13-acetate. Carcinogenesis, 7, 2059-2065.
76. Azuma,M., Momose,H. and Oyasu,R. (1990) In vitro malignant conversion of low-grade rat urinary bladder carcinoma cells by exposure to N-methyl-N-nitrosourea. Cancer Res., 50, 7062-7067.
77. Okamoto,M., Kawai,K., Reznikoff,C.A. and Oyasu,R. (1996) Transformation in vitro of a nontumorigenic rat urothelial cell line by hydrogen peroxide. Cancer Res., 56, 4649-4653.
78. Masters,J.R., Hepburn,P.J., Walker,L., Highman,W.J., Trejdosiewicz,L.K., Povey,S., Parkar,M., Hill,B.T., Riddle,P.R. and Franks,L.M. (1986) Tissue culture model of transitional cell carcinoma: Characterization of twenty-two human urothelial cell lines. Cancer Res., 46, 3630-3636.
79. Gunther,J.H., Jurczok,A., Wulf,T., Brandau,S., Deinert,I., Jocham,D. and Bohle,A. (1999) Optimizing syngeneic orthotopic murine bladder cancer (MB49). Cancer Res., 59, 2834-2837.
80. Hoffman,R.M. (1999) Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: A bridge to the clinic. Invest. New Drugs, 17, 343-359.
81. Booth,C., Harnden,P., Trejdosiewicz,L.K., Scriven,S., Selby,P.J. and Southgate,J. (1997) Stromal and vascular invasion in an human in vitro bladder cancer model. Lab. Invest., 76, 843-857.
82. Booth,C., Harnden,P., Selby,P.J. and Southgate,J. (2002) Towards defining roles and relationships for tenascin-C and TGFbeta-1 in the normal and neoplastic urinary bladder. J. Pathol., 198, 359-368.
83. Sarkar,S., Julicher,K.P., Burger,M.S. et al. (2000) Different combinations of genetic/epigenetic alterations inactivate the p53 and pRb pathways in invasive human bladder cancers. Cancer Res., 60, 3862-3871.
84. Ribeiro,J.C., Barnetson,A.R., Fisher,R.J., Mameghan,H. and Russell,P.J. (1997) Relationship between radiation response and p53 status in human bladder cancer cells [Erratum (1997) Int. J. Radiat. Biol., 72, 760]. Int. J. Radiat. Biol., 72, 11-20.
85. McIlwrath,A.J., Vasey,P.A., Ross,G.M. and Brown,R. (1994) Cell cycle arrests and radiosensitivity of human tumor cell lines: Dependence on wild-type p53 for radiosensitivity. Cancer Res., 54, 3718-3722.
86. Chang,F.L. and Lai,M.D. (2001) Various forms of mutant p53 confer sensitivity to cisplatin and doxorubicin in bladder cancer cells. J. Urol., 166, 304-310.
87. Masters,J.R., Bedford,P., Kearney,A., Povey,S. and Franks,L.M. (1988) Bladder cancer cell line cross-contamination: Identification using a locus-specific minisatellite probe. Br. J. Cancer, 57, 284-286.
88. Southgate,J., Proffitt,J., Roberts,P., Smith,B. and Selby,P. (1995) Loss of cyclin-dependent kinase inhibitor genes and chromosome 9 karyotypic abnormalities in human bladder cancer cell lines. Br. J. Cancer, 72, 1214-1218.
89. Masters,J.R., Thomson,J.A., Daly-Burns,B. et al. (2001) Short tandem repeat profiling provides an international reference standard for human cell lines. Proc. Natl Acad. Sci. USA, 98, 8012-8017.
90. Hicks,R.M. (1975) The mammalian urinary bladder: An accommodating organ. Biol. Rev. Camb. Philos. Soc., 50, 215-246.
91. Reznikoff,C.A., Johnson,M.D., Norback,D.H. and Bryan,G.T. (1983) Growth and characterization of normal human urothelium in vitro. In Vitro, 19, 326-343.
92. Kirk,D., Kagawa,S., Vener,G., Narayan,K.S., Ohnuki,Y. and Jones,L.W. (1985) Selective growth of normal adult human urothelial cells in serum-free medium. In Vitro Cell Dev. Biol., 21, 165-171.
93. Rahman,Z., Reedy,E.A. and Heatfield,B.M. (1987) Isolation and primary culture of urothelial cells from normal human bladder. Urol. Res., 15, 315-320.
94. Dubeau,L. and Jones,P.A. (1987) Growth of normal and neoplastic urothelium and response to epidermal growth factor in a defined serum-free medium. Cancer Res., 47, 2107-2112.
95. Hutton,K.A., Trejdosiewicz,L.K., Thomas,D.F. and Southgate,J. (1993) Urothelial tissue culture for bladder reconstruction: An experimental study. J. Urol., 150, 721-725.
96. Southgate,J., Hutton,K.A., Thomas,D.F. and Trejdosiewicz,L.K. (1994) Normal human urothelial cells in vitro: Proliferation and induction of stratification. Lab. Invest., 71, 583-594.
97. Southgate,J., Masters,J.R. and Trejdosiewicz,L.K. (2002) Culture of human urothelium. In Freshney,R.I.a.F., M.G. (eds), Culture of Epithelial Cells. J Wiley and Sons, Inc., NY, pp. 381-400.
98. Varley,C., Hill,G., Pellegrin,S., Shaw,N.J., Selby,P.J., Trejdosiewicz,L.K. and Southgate,J. (2005) Autocrine regulation of human urothelial cell proliferation and migration during regenerative responses in vitro. Exp. Cell Res., 306, 216-229.
99. Cilento,B.G., Freeman,M.R., Schneck,F.X., Retik,A.B. and Atala,A. (1994) Phenotypic and cytogenetic characterization of human bladder urothelia expanded in vitro. J. Urol., 152, 665-670.
100. Bindels,E.M., van der Kwast,T.H., Izadifar,V., Chopin,D.K. and de Boer,W.I. (2002) Functions of epidermal growth factor-like growth factors during human urothelial reepithelialization in vitro and the role of erbB2. Urol. Res., 30, 240-247.
101. Daher,A., de Boer,W.I., El-Marjou,A., van der Kwast,T., Abbou,C.C., Thiery,J.P., Radvanyi,F. and Chopin,D.K. (2003) Epidermal growth factor receptor regulates normal urothelial regeneration. Lab. Invest., 83, 1333-1341.
102. Freeman,M.R., Yoo,J.J., Raab,G., Soker,S., Adam,R.M., Schneck,F.X., Renshaw,A.A., Klagsbrun,M. and Atala,A. (1997) Heparin-binding EGF-like growth factor is an autocrine growth factor for human urothelial cells and is synthesized by epithelial and smooth muscle cells in the human bladder. J. Clin. Invest., 99, 1028-1036.
103. Varley,C.L., Stahlschmidt,J., Smith,B., Stower,M. and Southgate,J. (2004) Activation of peroxisome proliferator-activated receptor-gamma reverses squamous metaplasia and induces transitional differentiation in normal human urothelial cells. Am. J. Pathol., 164, 1789-1798.
104. Varley,C.L., Stahlschmidt,J., Lee,W.C., Holder,J., Diggle,C., Selby,P.J., Trejdosiewicz,L.K. and Southgate,J. (2004) Role of PPARgamma and EGFR signalling in the urothelial terminal differentiation programme. J. Cell Sci., 117, 2029-2036.
105. Cross,W.R., Eardley,I., Leese,H.J. and Southgate,J. (2005) A biomimetic tissue from cultured normal human urothelial cells: Analysis of physiological function. Am. J. Physiol. Renal. Physiol., 289, F459-F468.
106. Crallan,R.A., Lord,P.G., Rees,R.W. and Southgate,J. (2002) Inter-individual variation in urothelial DNA repair gene expression in vitro. Toxicol In Vitro, 16, 383-387.
107. Reznikoff,C.A., Loretz,L.J., Johnson,M.D. and Swaminathan,S. (1986) Quantitative assessments of the cytotoxicity of bladder carcinogens towards cultured normal human uroepithelial cells. Carcinogenesis, 7, 1625-1632.
108. 2 in normal uroepithelial cells. Int. J. Oncol., 17, 425-432.
109. Diggle,C.P., Pitt,E., Harnden,P., Trejdosiewicz,L.K. and Southgate,J. (2001) Role of p53 in the responses of human urothelial cells to genotoxic damage. Int. J. Cancer, 93, 199-203.
110. Mothersill,C., Harney,J., Lyng,F., Cottell,D., Parsons,K., Murphy,D.M. and Seymour,C.B. (1995) Primary explants of human uroepithelium show an unusual response to low-dose irradiation with cobalt-60 gamma rays. Radiat. Res., 142, 181-187.
111. Mothersill,C.E., O'Malley,K.J., Murphy,D.M. and Seymour,C.B. (1997) Apoptosis and other effects of radiation in normal human urothelial cells. Radiat. Oncol. Investig., 5, 150-153.
112. Mothersill,C.E., O'Malley,K.J., Murphy,D.M., Seymour,C.B., Lorimore,S.A. and Wright,E.G. (1999) Identification and characterization of three subtypes of radiation response in normal human urothelial cultures exposed to ionizing radiation. Carcinogenesis, 20, 2273-2278.
113. Reznikoff,C.A., Yeager,T.R., Belair,C.D., Savelieva,E., Puthenveettil,J.A. and Stadler,W.M. (1996) Elevated p16 at senescence and loss of p16 at immortalization in human papillomavirus 16 E6, but not E7, transformed human uroepithelial cells. Cancer Res., 56, 2886-2890.
114. Puthenveettil,J.A., Burger,M.S. and Reznikoff,C.A. (1999) Replicative senescence in human uroepithelial cells. Adv. Exp. Med. Biol., 462, 83-91.
115. Ramirez,R.D., Morales,C.P., Herbert,B.S., Rohde,J.M., Passons,C., Shay,J.W. and Wright,W.E. (2001) Putative telomere-independent mechanisms of replicative aging reflect inadequate growth conditions. Genes Dev., 15, 398-403.
116. Yeager,T.R., DeVries,S., Jarrard,D.F. et al. (1998) Overcoming cellular senescence in human cancer pathogenesis. Genes Dev., 12, 163-174.
117. Christian,B.J., Loretz,L.J., Oberley,T.D. and Reznikoff,C.A. (1987) Characterization of human uroepithelial cells immortalized in vitro by simian virus 40. Cancer Res., 47, 6066-6073.
118. Petzoldt,J.L., Leigh,I.M., Duffy,P.G., Sexton,C. and Masters,J.R. (1995) Immortalisation of human urothelial cells. Urol. Res., 23, 377-380.
119. Reznikoff,C.A., Yeager,T.R., Belair,C.D., Savelieva,E., Puthenveettil,J.A. and Stadler,W.M. (1996) Elevated p16 at senescence and loss of p16 at immortalization in human papillomavirus 16 E6, but not E7, transformed human uroepithelial cells. Cancer Res., 56, 2886-2890.
120. Reznikoff,C.A., Loretz,L.J., Christian,B.J., Wu,S.Q. and Meisner,L.F. (1988) Neoplastic transformation of SV40-immortalized human urinary tract epithelial cells by in vitro exposure to 3-methylcholanthrene. Carcinogenesis, 9, 1427-1436.
121. Bookland,E.A., Swaminathan,S., Oyasu,R., Gilchrist,K.W., Lindstrom,M. and Reznikoff,C.A. (1992) Tumorigenic transformation and neoplastic progression of human uroepithelial cells after exposure in vitro to 4-aminobiphenyl or its metabolites. Cancer Res., 52, 1606-1614.
122. Bookland,E.A., Reznikoff,C.A., Lindstrom,M. and Swaminathan,S. (1992) Induction of thioguanine-resistant mutations in human uroepithelial cells by 4-aminobiphenyl and its N-hydroxy derivatives. Cancer Res., 52, 1615-1621.
123. Swaminathan,S., Frederickson,S.M., Hatcher,J.F., Reznikoff,C.A., Butler,M.A., Cheever,K.L. and Savage,R.E.,Jr. (1996) Neoplastic transformation and DNA-binding of 4,4′-methylenebis(2-chloroaniline) in SV40-immortalized human uroepithehal cell lines. Carcinogenesis, 17, 857-864.
124. Puthenveettil,J.A., Frederickson,S.M. and Reznikoff,C.A. (1996) Apoptosis in human papillomavirus 16 E7-, but not E6-immortalized human uroepithelial cells. Oncogene, 13, 1123-1131.
125. Yeager,T.R. and Reznikoff,C.A. (1998) Methotrexate resistance in human uroepithehal cells with p53 alterations. J. Urol., 159, 581-585.
126. Bugajska,U., Georgopoulos,N.T., Southgate,J., Johnson,P.W., Graber,P., Gordon,J., Selby,P.J. and Trejdosiewicz,L.K. (2002) The effects of malignant transformation on susceptibility of human urothelial cells to CD40-mediated apoptosis. J. Natl Cancer Inst., 94, 1381-1395.
127. Shaw,N.J., Georgopoulos,N.T., Southgate,J. and Trejdosiewicz,L.K. (2005) Effects of loss of p53 and p16 function on life span and survival of human urothelial cells. Int. J. Cancer, 116, 634-639.
128. Meisner,L.F., Wu,S.Q., Christian,B.J. and Reznikoff,C.A. (1988) Cytogenetic instability with balanced chromosome changes in an SV40 transformed human uroepithelial cell line. Cancer Res., 48, 3215-3220.
129. Kao,C., Wu,S.Q., Bhatthacharya,M., Meisner,L.F. and Reznikoff,C.A. (1992) Losses of 3p, 11p, and 13q in EJ/ras-transformable simian virus 40-immortalized human uroepithelial cells. Genes Chromosomes Cancer, 4, 158-168.
130. Reznikoff,C.A., Belair,C., Savelieva,E., Zhai,Y., Pfeifer,K., Yeager,T., Thompson,K.J., DeVries,S., Bindley,C., Newton,M.A. et al. (1994) Long-term genome stability and minimal genotypic and phenotypic alterations in HPV16 E7-, but not E6-, immortalized human uroepithelial cells. Genes Dev., 8, 2227-2240.
131. Xu,C., Meikrantz,W., Schlegel,R. and Sager,R. (1995) The human papilloma virus 16E6 gene sensitizes human mammary epithelial cells to apoptosis induced by DNA damage. Proc. Natl Acad. Sci. USA, 92, 7829-7833.
132. Klingelhutz,A.J., Foster,S.A. and McDougall,J.K. (1996) Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature, 380, 79-82.
133. Reznikoff,C.A., Sarkar,S., Julicher,K.P., Burger,M.S., Puthenveettil,J.A., Jarrard,D.F. and Newton,M.A. (2000) Genetic alterations and biological pathways in human bladder cancer pathogenesis. Urol. Oncol., 5, 191-203.
134. Meister,G. and Tuschl,T. (2004) Mechanisms of gene silencing by double-stranded RNA. Nature, 431, 343-349.
135. Tomar,R.S., Matta,H. and Chaudhary,P.M. (2003) Use of adeno-associated viral vector for delivery of small interfering RNA. Oncogene, 22, 5712-5715.
136. Hieter,P. and Boguski,M. (1997) Functional genomics: It's all how you read it. Science, 278, 601-602.
137. Dillon,C.P., Sandy,P., Nencioni,A., Kissler,S., Rubinson,D.A. and Van Parijs,L. (2005) Rnai as an experimental and therapeutic tool to study and regulate physiological and disease processes. Annu. Rev. Physiol., 67, 147-173.